InvestorsHub Logo
Followers 74
Posts 15845
Boards Moderated 0
Alias Born 04/26/2010

Re: Sam81 post# 65800

Tuesday, 12/01/2015 1:01:54 PM

Tuesday, December 01, 2015 1:01:54 PM

Post# of 426487
Thanks for the link - looks like I owe BioChica a mea culpa - according to slide 5, patient population for ANCHOR is 36M, but R-IT, patients with TGs 150-199, adds another 34M people - doubles addressable population - that's huge. Guess I just forgot! <sheepish grin>

Also answers a question that's been floating around here - they ARE promoting JELIS:


Broader Opportunity via Court Decision: declaratory judgment in August 2015 allows for education of physicians regarding ANCHOR trial results

? Now allowed to communicate more data to physicians, including results of ANCHOR and JELIS trials, subject to disclaimers



Slide 18 is entirely devoted to CHERRY study! Odd that diluted share count on slide 19 is 244M - they aren't counting convertible debt owned by the BB's like HDG does.

The Thought Police: To censor and protect. Craig Bruce

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News